Table 2.
Age, sex (M/F), duration of illnesses (d), HIV RNA values, and antiretroviral treatments of HIV infected children.
| n | Age (years) | M/F | d(years) | HIV RNAcopies/mL | ART |
| 1 | 15.5 | F | 7.0 | UD | 3TC, AZT, LPV/r |
| 2 | 16.5 | M | 16.3 | UD | 3TC, AZT, LPV/r |
| 3 | 18.5 | F | 9.0 | UD | 3TC, AZT, LPV/r |
| 4 | 8.3 | M | 5.0 | 478,000 | AZT, LPV/r, TDF |
| 5 | 12.4 | M | 4.0 | UD | EFV, 3TC, DTG |
| 6 | 10.0 | F | 9.9 | 44,080 | AZT, LPV/r, TDF |
| 7 | 11.8 | F | 11.0 | UD | 3TC, AZT, LPV/r |
| 8 | 14.7 | F | 3.0 | UD | 3TC, AZT, LPV/r |
| 9 | 9.4 | F | 9.4 | UD | 3TC, AZT, LPV/r |
| 10 | 14.0 | M | 9.0 | UD | 3TC, AZT LPV/r |
| 11 | 9.0 | M | 9.0 | UD | 3TC, AZT, LPV/r |
| 12 | 6.2 | M | 6.0 | UD | 3TC, AZT, LPV/r |
| 13 | 11.1 | F | 6.0 | UD | 3TC, AZT, LPV/r |
| 14 | 16.9 | M | 0.5 | UD | Elvitegravir/cobicistat/FTC/TDF |
| 15 | 15.1 | M | 0.5 | UD | Elvitegravir/cobicistat/FTC/TDF |
| 16 | 12.2 | M | 3.0 | 12,592 | 3TC, AZT, NVP |
| 17 | 11.5 | F | 11.5 | 29,252 | 3TC, AZT, LPV/r |
| 18 | 14.9 | F | 3.0 | UD | 3TC, AZT, LPV/r |
| 19 | 0.5 | M | 0.5 | 298,720 | 3TC, AZT, LPV/r |
| 20 | 11.0 | F | 6.0 | UD | 3TC, AZT, DTG |
| 21 | 16.3 | M | 1.3 | 896,938 | 3TC, AZT, DTG |
ART: Antiretroviral treatment, AZT: zidovudine, DTG: dolutegravir, EFV: efavirenz, F: female, FTC: emtricitabine, HIV: human immunodeficiency virus, LPV/r: lopinovir/ritonavir, M: male, n: number of patients, NVP: Nevirapine, TDF: tenofovir disoproxil fumarate, UD: undetermined, 3TC: lamivudine.